Products - Ear, nose and throat conditions | Topic | NICE

Showing 8 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
5 February 2025
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
12 February 2025
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
11 September 2025
Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis (Review of TA648) [ID6480]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
11 September 2025
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
12 November 2025
Benralizumab for previously treated severe nasal polyps [ID1659]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Depemokimab for treating chronic rhinosinusitis with nasal polyps ID 6449
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years TSID 12054
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC